Institutional asset managers, specialized healthcare venture capital funds, and dedicated life science investment firms hold the vast majority of common equity shares in Tenaya Therapeutics. Major stakeholders include prominent institutional investment powerhouses, founding venture capital incubators, and corporate insiders whose holdings align with the long-term clinical advancement of its cardiovascular pipelines.